Last reviewed · How we verify
Dysport (R) — Competitive Intelligence Brief
phase 3
Botulinum toxin type A
SNARE complex (synaptosome-associated protein)
Neurology, Aesthetics, Movement Disorders
Small molecule
Live · refreshed every 30 min
Target snapshot
Dysport (R) (Dysport (R)) — Department of Medical Services Ministry of Public Health of Thailand. Dysport is a botulinum toxin type A preparation that blocks acetylcholine release at the neuromuscular junction, causing temporary muscle paralysis.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Dysport (R) TARGET | Dysport (R) | Department of Medical Services Ministry of Public Health of Thailand | phase 3 | Botulinum toxin type A | SNARE complex (synaptosome-associated protein) | |
| NT 201 | NT 201 | Merz Aesthetics GmbH | marketed | Botulinum toxin type A | SNARE complex (acetylcholine release machinery) | |
| Botox infiltration | Botox infiltration | University Rovira i Virgili | marketed | Neurotoxin; botulinum toxin type A | SNARE complex (synaptosome-associated protein); acetylcholine release machinery | |
| Intradetrusor Botox Injections | Intradetrusor Botox Injections | The Methodist Hospital Research Institute | marketed | Neurotoxin; botulinum toxin type A | SNARE complex (synaptosomal-associated protein); acetylcholine release machinery | |
| PrabotulinumtoxinA-Xvfs | PrabotulinumtoxinA-Xvfs | Lupo Center for Aesthetic and General Dermatology | marketed | Botulinum toxin type A | SNARE complex (acetylcholine release machinery) | |
| powder BoNT-A (BOTOX/Vistabel) | powder BoNT-A (BOTOX/Vistabel) | Galderma R&D | marketed | Neurotoxin; botulinum toxin type A | SNAP-25 (synaptosome-associated protein of 25 kDa) | |
| OnabotulinumtoxinA 100 UNT [Botox] | OnabotulinumtoxinA 100 UNT [Botox] | Women and Infants Hospital of Rhode Island | marketed | Neurotoxin; botulinum toxin type A | SNAP-25 (synaptosome-associated protein of 25 kDa) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Botulinum toxin type A class)
- Merz North America, Inc. · 2 drugs in this class
- Department of Medical Services Ministry of Public Health of Thailand · 2 drugs in this class
- Brigitte Schürch · 1 drug in this class
- Carruthers Dermatology Centre · 1 drug in this class
- Galderma R&D · 1 drug in this class
- Huons Co., Ltd. · 1 drug in this class
- Innovaderm Research Inc. · 1 drug in this class
- Lupo Center for Aesthetic and General Dermatology · 1 drug in this class
- Merz Aesthetics GmbH · 1 drug in this class
- Multiple Sclerosis Center of Northeastern New York · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Dysport (R) CI watch — RSS
- Dysport (R) CI watch — Atom
- Dysport (R) CI watch — JSON
- Dysport (R) alone — RSS
- Whole Botulinum toxin type A class — RSS
Cite this brief
Drug Landscape (2026). Dysport (R) — Competitive Intelligence Brief. https://druglandscape.com/ci/dysport-r. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing